BioVaxys Technology Corp Ordinary Shares BVAXF
Trading Information
- Previous Close Price
- $0.09
- Day Range
- $0.07–0.09
- 52-Week Range
- $0.01–0.21
- Bid/Ask
- $0.07 / $0.09
- Shares Outstanding
- 40.65M
- Market Cap
- $3.35M
- Volume/Avg
- 23,536 / 28,018
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious diseases, antigen desensitization, and other immunological fields. The company's clinical-stage pipeline includes maveropepimut-S, which is in Phase II clinical development for Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum-resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform, which is soon to enter Phase I in Spain for treating refractory late-stage ovarian cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 0
- Website
- https://www.biovaxys.com
Valuation
|
Metric
|
BVAXF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BVAXF
|
|---|---|
Quick Ratio | 0.10 |
Current Ratio | 0.28 |
Interest Coverage | — |
Quick Ratio
BVAXF
Profitability
|
Metric
|
BVAXF
|
|---|---|
Return on Assets (Normalized) | −345.06% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
BVAXF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|bhwp$M | LOCK|Vjb%< | $136B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<tvn?x | LOCK|rM&B> | $84B | |||
| Moderna Inc
MRNA
| LOCK|TWtPY$b | LOCK|^S | $81B | |||
| argenx SE ADR
ARGX
| LOCK|^tSVyVZ | LOCK|Q>B | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|s$SF%PY | LOCK|<Z | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>LrMQg | LOCK|f^@R$ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|kv#$$Nk | LOCK|zF!f | $28B | |||
| Incyte Corp
INCY
| LOCK|l>>Xs# | LOCK|%S$ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|?#cGc< | LOCK|LwT | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>&%>l# | LOCK|j< | $14B |
United States